Weiyuan
Latest round
- Series A
Last raised
- Mar 2026
Total raised
- $43M
Investors
- 1
About Weiyuan
Established in 2023 and based in Hangzhou, China, Weiyuan operates as a synthetic biology service company that provides synthetic biology service. The company has an R&D center and pilot site in the field of synthetic biology. The CEO as well as the founder, Wu Yan, graduated from Zhejiang University, and the CTO, Luo Zhibo, graduated from Tsinghua University and Melbourne University. It was awarded as innovative small and medium-sized enterprises in Zhejiang Province. Some enterprises, such as Sinopep, Titan Purchase Contract, and Huadong Medicine, have cooperated with the company. Weiyuan uses high-throughput screening platform for engineered strains and AI evolution platform for industrialized enzymes to provide enzyme evolution, peptide industrialization, functional protein customization and nucleotide modification services. The company's products include active biologics and chiral chemicals. The company generates revenue by offering enzyme evolution, peptide industrialization, functional protein customization and nucleotide modification services.
Who invested in Weiyuan
1 investor across 1 round
See all investors in Weiyuan
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 30, 2026
Amount
$43M
Investors
Questions about Weiyuan
Who invested in Weiyuan?
Weiyuan has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Weiyuan raised?
Weiyuan has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Weiyuan last raise money?
Weiyuan's most recent round on record is a Series A, in Mar 2026.
What does Weiyuan do?
Established in 2023 and based in Hangzhou, China, Weiyuan operates as a synthetic biology service company that provides synthetic biology service.
Where is Weiyuan headquartered?
Weiyuan is headquartered in Hangzhou City, China.
Which VCs invest in companies like Weiyuan?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Weiyuan's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Weiyuan? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.